Metformin Testing Prompts New Finding Of NDMA And Cancer Risk
FDA Asks Several Manufacturers To Recall Products In US
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.
You may also be interested in...
An online pharmacy that tests medications before dispensing them advocated for regulations requiring independent testing and verification of the chemical content of pharmaceuticals; it also alleged that the US FDA’s testing method for evaluating the carcinogenic risk of metformin needs refinement.
The US FDA finds metformin meets NDMA impurity threshold and urges diabetics to continue taking it.
Ranitidine no more carcinogenic than grilled meat, the FDA’s Woodcock says, with NDMA levels well below those claimed by Valisure.